
MILESTONE SCIENTIFIC INC.
90
Recent developments include leadership transition, completion of debt-to-equity conversion, narrowing net losses with revenue growth guidance, and ongoing commercial rollout of the CompuFlo Epidural System.
- Milestone Scientific announced a leadership transition and outlined future plans in May 2026 [N3].
- The company completed a debt-to-equity conversion with board members at $0.50 per share in August 2026 [N2].
- Milestone reported narrowing net loss in Q4 and indicated revenue growth of approximately 9% to 14% for fiscal year 2026 [N4].
- Commercial rollout of the CompuFlo Epidural System continued with launches at multiple pain management clinics, including The Painless Center in New Jersey [N8].
- Benchmark maintained a speculative buy recommendation on Milestone Scientific in November 2025 [N5].
- Eric Hines was appointed Chief Executive Officer in August 2025 [N7].
Milestone Scientific Inc. develops and commercializes advanced injection technologies primarily for dental and medical applications. Its dental product line, including the STA Single Tooth Anesthesia System, constitutes the majority of its revenue. The company is actively expanding its medical product commercialization, particularly the CompuFlo Epidural Computer Controlled Anesthesia System, which has received FDA 510(k) clearance, CE mark approval, and a Category III CPT code to support reimbursement. Milestone operates internationally with a distribution network spanning over 30 countries and sources key components from China, exposing it to geopolitical and trade risks. The company has reported net losses in recent periods and is working to regain compliance with NYSE American listing standards. Leadership changes and strategic initiatives have been announced to support growth and innovation.
Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. Milestone Scientific Inc. is a smaller reporting company listed on NYSE American (MLSS) that primarily generates revenue from dental products, notably the STA Single Tooth Anesthesia System. The company is expanding commercialization of its medical product line, including the CompuFlo Epidural System, which has regulatory clearances and reimbursement codes but faces adoption challenges. As of September 30, 2026, Milestone reported a net loss of $747,545 and had cash and equivalents of $1.2 million with a current ratio of 2.06. The company faces risks related to trade tensions, international operations, and compliance with NYSE listing standards due to equity levels and sustained losses. Recent developments include leadership changes, debt-to-equity conversion, and commercial rollout of medical products.
Milestone Scientific's regulatory clearances and reimbursement codes for its medical products, combined with ongoing commercial rollout and expanding adoption, provide a foundation for revenue growth beyond its established dental product line. Leadership transitions and strategic partnerships may enhance execution capabilities. The company's ability to manage trade and geopolitical risks while expanding international sales could strengthen its market presence. Successful debt-to-equity conversions improve the capital structure, potentially supporting operational stability.
Milestone Scientific faces risks from slow adoption of its medical products, leading to inventory allowances and uncertain recovery of commercialization investments. Trade tensions and geopolitical instability, especially related to China as a supplier and market, may disrupt supply chains and sales. The company has reported sustained net losses and equity levels below NYSE American listing standards, risking delisting. Additional financing needs pose execution risks if capital is not available on reasonable terms. Fluctuations in product mix and pricing pressures could adversely impact margins and profitability.
Milestone Scientific's moat is centered on its proprietary injection technologies, including the STA Single Tooth Anesthesia System and the CompuFlo Epidural System, which have regulatory clearances and reimbursement codes that support market adoption. The company's specialized technology and regulatory approvals create barriers to entry for competitors. However, the moat is challenged by the need for broader clinician adoption, reimbursement uncertainties, and competition in both dental and medical markets. The company's international distribution network and ongoing product innovation contribute to its competitive positioning.
• Dependence on Dental Product Line: A significant portion of revenue comes from dental products, particularly the STA Single Tooth Anesthesia System. Declines in demand, competition, pricing pressures, or distribution disruptions could materially affect financial results [S2].
• Medical Product Commercialization Challenges: Adoption of medical products like the CompuFlo Epidural System may be slower than anticipated, with reimbursement uncertainties and competition limiting revenue generation. Inventory allowances indicate risk of slow sales [S2].
• Trade and Geopolitical Risks: The company sources components from China and generates revenue internationally, exposing it to risks from tariffs, trade tensions, export controls, and geopolitical instability that could disrupt supply chains and sales [S2].
• NYSE American Listing Compliance: Milestone's stockholders' equity is below NYSE American continued listing standards, and sustained losses increase delisting risk. Failure to regain compliance by April 8, 2027, could lead to delisting and adversely impact stock value and liquidity [S2].
• Financing Needs and Liquidity: The company expects to require additional financing to fund operations and execute its business plan. Availability of capital on reasonable terms is uncertain, posing risks to ongoing operations and listing status [S2].
Business trends: Expansion of medical product commercialization alongside established dental product revenue; international sales growth amid geopolitical challenges.
Execution milestones: Leadership transition, debt-to-equity conversion, commercial rollout of CompuFlo Epidural System, and efforts to regain NYSE American listing compliance.
Key risks: Slow adoption of medical products, trade and geopolitical uncertainties, sustained net losses, and potential NYSE delisting due to equity thresholds.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Milestone Scientific Inc. is a smaller reporting company incorporated in Delaware with common stock listed on NYSE American under ticker MLSS [S1].
- The company derives a significant portion of its revenue from dental products, especially the STA Single Tooth Anesthesia System and related handpieces [S2].
- Milestone is expanding commercialization of medical products, notably the CompuFlo Epidural Computer Controlled Anesthesia System, which has FDA 510(k) clearance, CE mark approval for Europe, and a Category III CPT code for reimbursement submissions [S2].
- The company has experienced slower adoption of medical products, maintaining a material allowance against slow-moving medical finished goods inventory [S2].
- Milestone Scientific sources important product components from China and generates meaningful revenue internationally, including from China, which exposes it to geopolitical and trade risks [S2].
- The company reported total stockholders' equity of approximately $3.7 million as of September 30, 2026, below NYSE American continued listing standards, and has submitted a plan to regain compliance [S2].
- As of September 30, 2026, Milestone had cash and equivalents of $1.2 million and current assets of approximately $6.77 million against current liabilities of about $3.28 million, yielding a current ratio of 2.06 and cash ratio of 0.37 [S2].
- The company reported a net loss of $747,545 and basic and diluted EPS of -$0.01 for the quarter ended September 30, 2026 [S2].
- Milestone completed a debt-to-equity conversion with board members at $0.50 per share in August 2026 [N2].
- Eric Hines was appointed Chief Executive Officer in August 2025 [N7].
- Milestone has launched the CompuFlo Epidural System commercially at multiple pain management and spine clinics, including The Painless Center in New Jersey and Pain Doctors Medical LLC [N8].
- The company has expanded adoption of the CompuFlo Epidural System following Medicare price approvals in multiple states [N8].
- Milestone announced leadership transition and future plans in May 2026 [N3].
- The company reported narrowing net loss in Q4 and indicated revenue growth of approximately 9% to 14% for fiscal year 2026 [N4].
- Benchmark maintained a speculative buy recommendation on Milestone Scientific in November 2025 [N5].
Generated 2026-11-13
- S1 | 2026-05-05 | 10-K/A
- S2 | 2026-11-13 | 10-Q
- N1 | 2026-09-18 | www.nasdaq.com | Weekly Buzz: RARE, BAYRY Win Approvals; SION Cuts Jobs, GSK Deals; AZN, RHHBY Lead | https://www.nasdaq.com/articles/weekly-buzz-rare-bayry-win-approvals-sion-cuts-jobs-gsk-deals-azn-rhhby-lead
- N2 | 2026-08-26 | www.nasdaq.com | Milestone Completes Debt-To-Equity Conversion With Board Members At $0.50 Per Share | https://www.nasdaq.com/articles/milestone-completes-debt-equity-conversion-board-members-050-share
- N3 | 2026-05-05 | www.nasdaq.com | Milestone Scientific Announces Leadership Transition and Future Plans | https://www.nasdaq.com/articles/milestone-scientific-announces-leadership-transition-and-future-plans
- N4 | 2026-04-01 | www.nasdaq.com | Milestone Scientific Q4 Net Loss Narrows; Expects Approx. 9% To 14% Revenue Growth In FY26;Stock Up | https://www.nasdaq.com/articles/milestone-scientific-q4-net-loss-narrows-expects-approx-9-14-revenue-growth-fy26stock
- N5 | 2025-11-20 | www.nasdaq.com | Benchmark Maintains Milestone Scientific (MLSS) Speculative Buy Recommendation | https://www.nasdaq.com/articles/benchmark-maintains-milestone-scientific-mlss-speculative-buy-recommendation
- N6 | 2025-11-14 | www.nasdaq.com | Applied Therapeutics, Omeros, And Others Post Sharp Moves After Market Close | https://www.nasdaq.com/articles/applied-therapeutics-omeros-and-others-post-sharp-moves-after-market-close
- N7 | 2025-08-01 | www.nasdaq.com | Milestone Scientific Appoints Eric Hines As Chief Executive Officer | https://www.nasdaq.com/articles/milestone-scientific-appoints-eric-hines-chief-executive-officer
- N8 | 2025-07-17 | www.nasdaq.com | Milestone Scientific Inc. Launches CompuFlo® Epidural System at The Painless Center in New Jersey | https://www.nasdaq.com/articles/milestone-scientific-inc-launches-compuflor-epidural-system-painless-center-new-jersey
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


